

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1-4. (Canceled).

5. (Previously Presented) (2R,3S,4R)-2-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide.

6. (Canceled).

7. (Previously Presented) A compound selected from the group consisting of (2R,3R,4S,5R)-2-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrothiophene-3,4-diol, (2R,3R,4S,5R)-2-(2-chloro-6-methylaminopurin-9-yl)-5-hydroxymethyl-tetrahydrothiophene-3,4-diol, (2S,3S,4R,5R)-5-(6-amino-2-chloro-purin-9-yl)-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide, (2S,3S,4R,5R)-5-(2-chloro-6-methylaminopurin-9-yl)-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide, and (2S,3S,4R,5R)-5-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide.

8. (Canceled).

9. (Currently Amended) ~~The compound of claim 8, which is~~ (2S,3R,4S,5R)-2-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrothiophene-3,4-diol.

10-20. (Canceled).

21. (Previously Presented) A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.

22. (Canceled).

23. (Previously Presented) A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.

24. (Canceled).